APG Healthcare Orlando: SPRAVATO™ for TRD Now Available
Understanding Treatment-Resistant Depression (TRD) and SPRAVATO™ Treatment-resistant depression (TRD) impacts countless individuals, representing a significant challenge in mental healthcare. Many experience little to no relief from traditional antidepressant medications, leading to persistent symptoms and diminished quality of life. SPRAVATO™ (esketamine), a novel nasal spray, offers a different approach to treating TRD. Unlike conventional antidepressants that primarily target serotonin and norepinephrine, esketamine modulates glutamate receptors in the brain, a neurotransmitter system implicated in depression....